Defunct Company
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
429
NCT02936323
PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Phase: Phase 1/2
Role: Lead Sponsor
Start: Dec 8, 2016
Completion: Feb 25, 2021
NCT03221400
PEN-866 in Patients With Advanced Solid Malignancies
Start: Aug 29, 2017
Completion: Jun 30, 2023